Study found DNA-based screen was more than 90 percent accurate in predicting recurrence
by pancreaticgary on Thu Aug 07, 2008 12:00 AM
Today I began my 19th Cycle (28 day/cycle) of RAD001. The Phase 2 Trial I was on has ended but I am continuing on the RAD.Last weeks scans showed no change from the initial tumor reductions when I began the Phase 2 Trial, all is stable. (There was some slight tumor reduction on some scans prior to these but it appears that there were no further reductions this time).
Still feeling good and very fortunate.
Gary Lombardi- New Hampshire, Non -operable Non-functioning Islet Cell Pancreatic Cancer with Mets to the liver, dx March 2006. Temodar chemo for 6 months prior to entering drug trial.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.